• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Emflaza (deflazacort)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Emflaza (deflazacort)

  • Profile

Profile

Contact Information

Contact: PTC Therapeutics
Website: https://www.emflaza.com/

Currently Enrolling Trials

    Show More

    General Information

    Emflaza (deflazacort) is a corticosteroid which exerts anti-inflammatory and immunosuppressive effects.

    Emflaza is specifically indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients two (2) years of age and older.

    Emflaza is supplied as a tablet or oral suspension. The recommended dose is approximately 0.9 mg/kg/day once daily. If tablets are used, round up to the nearest possible dose. Any combination of the four Emflaza tablet strengths (6 mg, 18 mg, 30 mg, and 36 mg) can be used to achieve this dose. If the oral suspension is used, round up to the nearest tenth of a milliliter (mL).  Both the tablets and oral suspension can be taken with or without food

    Mechanism of Action

    Emflaza (deflazacort) is a corticosteroid prodrug, whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown.

    Side Effects

    Adverse effects associated with the use of Emflaza may include, but are not limited to, the following:

    • Cushingoid appearance
    • weight increased
    • increased appetite
    • upper respiratory tract infection
    • cough
    • pollakiuria
    • hirsutism
    • central obesity
    • nasopharyngitis

    Clinical Trial Results

    The FDA approval of Emflaza was based on  a multicenter, randomized, double-blind, placebo-controlled, 52-week study conducted in the United States and Canada. The study population consisted of 196 male pediatric patients 5 to 15 years of age who were ambulatory and non-ambulatory. The patients were randomized to therapy with deflazacort (0.9 or 1.2 mg/kg/day), an active comparator or placebo. After 12 weeks, placebo patients were re-randomized to receive either deflazacort or the active comparator for an additional 40 weeks. A comparison to placebo was made after 12 weeks of treatment. Efficacy was evaluated by assessing the change between Baseline and Week 12 in average strength of 18 muscle groups. The change in average muscle strength score between Baseline and Week 12 was significantly greater for the deflazacort 0.9 mg/kg/day dose group, the recommended dose, than for the placebo group (p=0.017). Increases in muscle strength continued through the 52 week duration of the study demonstrating persistence of the treatment effect observed at Week 12. Results on several timed measures of patient function (i.e., time to stand from supine, time to climb four stairs and time to walk or run 30 feet) also numerically favored deflazacort 0.9 mg/kg/day at Week 12, in comparison with placebo.

    Approval Date: 2017-02-01
    Company Name: PTC Therapeutics
    Back to Listings

    Upcoming Events

    • 12Apr

      The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    • White House

      Trial Stakeholders Advise White House on Emergency Research Infrastructure

    • SurveywBlueBackground-360x240.png

      Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing